Health News Releases

  • Today October 19
October 18, 11:05
Future Health Launches Global Challenge to Move Health Innovation Towards Real-world Application
Future Health - A Global Initiative by Abu Dhabi opened applications for the Future Health Digital Innovation Challenge 2026, welcoming innovators from around the world to develop AI, software, and co
October 16, 14:30
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54621245&newsitemid=20261014178348&lan=en-US&anchor=TSE%3A4
October 16, 12:00
New Study Brings Ketogenic Therapy for Bipolar Disorder Directly to Rural Alabama Homes
Baszucki Group today announced funding for a clinical study to examine the impact of ketogenic therapy on people living with bipolar disorder in rural Central Alabama. This study, led by researchers a
October 15, 15:30
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the
October 15, 14:35
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of
October 15, 09:49
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54622338&newsitemid=20261014922379&lan=en-US&anchor=TSE%3A4
October 14, 17:18
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering
Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, f
AesMed Hair Care Day Campaign 2026
October 14, 09:00
AesMed Expands 1111 Hair Care Day Campaign 2026 to Support Hair Loss Patients and Promote Global Awareness
AesMed Co., Ltd. (https://www.aesmed.co.kr/main), a company specializing in science-based hair loss care solutions in Korea, announced it will continue the 1111 Hair Care Day Campaign 2026 (https://ww
October 13, 14:37
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing
Galderma (SIX: GALD) today announced new global research revealing that more than half (56%) of women first put menopause-related skin changes down to general ageing, while only less than a third of w
October 13, 10:30
Doctors, Public Health Experts and Dental Leaders Call for Oral Health to Become Part of Everyday Health Care
Doctors, public-health experts and dental leaders are calling for oral health to be treated as part of overall health. Their message is clear: healthier teeth and gums matter beyond the mouth, and eff
October 12, 17:20
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Agenus Inc. (https://www.agenusbio.com/) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizat
October 08, 16:00
ClaroNav Kolahi Inc. Announces EU MDR Certification for Navient Surgical Navigation System
ClaroNav Kolahi Inc. (CKI), a global developer and manufacturer of surgical navigation technologies, today announced that its Navient Surgical Navigation System has received certification under the Eu
October 08, 14:34
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Cli
October 08, 14:15
Medisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical Compounding
Medisca and EUROAPI have formed a strategic partnership focused on expanding API access for pharmaceutical compounding, creating differentiated access in North America and establishing a broader frame
October 08, 11:40
Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment
Rivercell, a Paris-based biotechnology and AI company building its own data infrastructure on how human cells respond to any treatment and training a world model of the cell that can predict those res
October 07, 17:00
MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why lif
October 07, 11:20
Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite
Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation s
October 06, 16:10
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation
Galderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30 years since Restylane was launched in Europe as the first hyaluronic acid (HA) injectable.[1] With HA closest to the skin
SOFIE Biosciences has 15 CMO sites across the U.S., manufacturing PET radiopharmaceutical products
October 06, 09:33
GE HealthCare to Acquire SOFIE Biosciences, Establishing a ‘Final Mile’ Footprint for PET Radiopharmaceutical Supply in the U.S.
GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase pr
October 05, 15:35
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus Inc. (https://www.agenusbio.com/) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1
October 05, 14:50
LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion
Nearly half the world’s population is affected by oral disease - and the number of cases is rising. This World Smile Day, LISTERINE® is launching Oral Care Counts - a multiyear education and advocacy
October 05, 12:10
Global Health Leaders to Convene at Abu Dhabi Future Health Summit 2026
Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better ant
October 05, 11:30
Roquette to Showcase End-to-End Pharma Solutions for Patient-Centric Formulations at CPHI Milan 2026
Roquette will showcase its end-to-end portfolio of pharmaceutical excipients, drug delivery solutions and leading technical expertise at CPHI Milan 2026 in Italy, where the company will welcome visito
October 02, 11:50
Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair
Neutrogena®, Aveeno®, and Regaine®* will present 12 new scientific data sets at the 35th European Academy of Dermatology and Venereology (EADV) Congress taking place September 30th through October 3rd
October 02, 09:54
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreem
25 per page50 per page75 per page100 per page